
Can PRRT Be Made More Effective Against NET Liver Metastases? An interesting hybrid approach using 177Lu-DOTATATE
Researchers and clinicians are actively exploring multiple strategies to enhance Peptide Receptor Radionuclide Therapy (PRRT) and make it more effective and personalised for neuroendocrine tumour
















